3 results
Primary Objective:The purpose of Part A is to determine whether sutimlimab administration results in a greater than or equal to (>=)1.5 gram per deciliter (g/dL) increase in hemoglobin (Hgb) level and avoidance of transfusion in participants…
This study has been transitioned to CTIS with ID 2023-505321-14-00 check the CTIS register for the current data. Primary Objective:Efficacy of nipocalimab in participants with warm autoimmune hemolytic anemia (wAIHA)The key secondary objectives of…
The aim of this study is to determine whether LNP023 is effective and safe for the treatment of PNH. LNP023 is compared to the Standard of Care (SOC) anti-C5 antibody treatment. The primary objectives are to:• Demonstrate superiority of LNP023…